Dr. Reddy’s to Ring NYSE Closing Bell Marking 25 Years on Wall Street
Memorial Day Sale – Claim 70% Off TipRanks
- Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
- Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter
Dr Reddy’s Laboratories ( (RDY) ) has issued an announcement.
Dr. Reddy’s Laboratories announced on May 28, 2026 that it will ring the Closing Bell at the New York Stock Exchange on May 29, 2026 to mark 25 years since its NYSE listing, a milestone dating back to April 2001 when it became the first Asian pharmaceutical company outside Japan to list on the exchange. The ceremony, to be led by Chairman Satish Reddy and the senior management team and livestreamed from NYSE headquarters in New York, underscores the company’s long-term presence in U.S. capital markets and reinforces its positioning as a trusted provider of differentiated pharmaceutical products backed by consistent operations and strong governance.
The event highlights Dr. Reddy’s strategic focus on the U.S. market and its continued commitment to global standards of transparency and innovation, themes the chairman linked to the founding vision of delivering affordable, innovative medicines worldwide. For investors and other stakeholders, the anniversary celebration signals continuity in the company’s global ambitions and its intent to maintain a prominent profile among international healthcare issuers, even as it continues investing in future-oriented businesses and ESG-led initiatives.
The most recent analyst rating on (RDY) stock is a Buy with a $16.90 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Neutral.
The score is driven mainly by solid but weakening fundamentals (margin/ROE compression and higher debt despite growth) and a balanced earnings-call outlook that points to FY27 margin recovery but highlights near-term profitability and working-capital risks. Technicals are neutral-to-soft and valuation support is limited given the P/E and low yield.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories is a global pharmaceutical company headquartered in Hyderabad, India, founded in 1984 and focused on expanding access to affordable and innovative medicines. Its portfolio spans APIs, generics, branded generics, biosimilars and OTC products across key therapeutic areas such as gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology, with major markets in the U.S., India, Russia and CIS, China, Brazil and Europe.
The company emphasizes deep scientific capabilities and has a track record of industry firsts, while positioning itself as an early adopter of sustainability and ESG practices. Its stated ESG goals target environmental stewardship, improved access and affordability, diversity and strong governance, reinforcing its ambition to remain a trusted healthcare player in regulated markets worldwide.
Average Trading Volume: 2,555,507
Technical Sentiment Signal: Buy
Current Market Cap: $11.55B
See more insights into RDY stock on TipRanks’ Stock Analysis page.
